The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
Open accessAbstract
SNF'ing out antitumor immunity: Immune checkpoint inhibitors induce durable tumor regressions in some, but not all, cancer patients. Understanding the mechanisms that determine tumor sensitivity to these drugs could potentially expand the number of patients who benefit (see the Perspective by Ghorani and Quezada). Pan et al. discovered that tumor cells in which a specific SWI/SNF chromatin remodeling complex had been experimentally inactivated were more sensitive to T cell–mediated killing. The cells were more responsive to interferon-γ, leading to increased secretion of cytokines that promote antitumor immunity. Miao et al. examined the genomic features of tumors from patients with metastatic renal cell carcinoma who had been treated with immune checkpoint inhibitors. Tumors harboring inactivating mutations in PBRM1 , which encodes a subunit of the same SWI/SNF complex, were more likely to respond to the drugs. Science , this issue p. 770 , p. 801 ; see also p. 745
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Pooled in vivo and in vitro CRISPR-Cas9 based screening have nominated several tumour intrinsic drivers of resistance to immunotherapy 4,8-11 , but therapeutic applications of these findings remain limited.”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [10]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“thus it is surprising that TBK1 has been nominated as a candidate immune evasion gene 4,9-11”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [10]
Experimental — accuracy not yet measuredIn the citing paper
“CRISPR/Cas9 KO screens in murine models or engineered human cell lines testing tumor-T cell interactions identified putative novel mechanisms of immune evasion involving chromatin regulators10, TNFα signaling11, SOX412, PTPN213, and APLNR10, yet their clinical relevance is unclear.”
From Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion (2021) · cites this paper as [12]
In the citing paper
“consistent with prior reports12, induction of CD49f, which encodes an integrin associated with epithelial-to-mesenchymal transition (EMT).”
From Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion (2021) · cites this paper as [12]
In the citing paper
“In previous screens, antigen-specific T cells targeting model tumor associated antigen (TAA), such as OVA, gp100, and NY-ESO-1, were used (Manguso et al., 2017; Pan et al., 2018; Patel et al., 2017).”
From Protein Barcodes Enable High-Dimensional Single-Cell CRISPR Screens (2018) · cites this paper as Pan et al., 2018
In the citing paper
“Several studies have demonstrated that mutations in genes involved in the SWI-SNF chromatin remodeling complex may sensitize human tumors to ICIs and that treatment with an epigenetic modulator can potentiate the ICI-mediated antitumor response through increased production of chemokines responsible for recruiting CD8 + T cells (104-107).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Self-citationTrapnell, C., Williams, B. A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M. J., Salzberg, S. L., Wold, B. J., & Pachter, L. (2010) · Nature Biotechnology · doi:10.1038/nbt.1621 · Cited by 15,556
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 857
Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
Ladanyi, M., Sánchez-Vega, F., & Zauderer, M. G. (2019) · Genome Medicine · doi:10.1186/s13073-019-0631-0 · Cited by 69
Multilevel Mechanisms of Cancer Drug Resistance
Roszkowska, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212402 · Cited by 73
A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response
Hakimi, A. A., Attalla, K., DiNatale, R. G., Ostrovnaya, I., Flynn, J. R., Blum, K. A., Ged, Y. M. A., Hoen, D. R., Kendall, S. M., Reznik, E., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17965-0 · Cited by 68
MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
Shklovskaya, E., & Rizos, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136741 · Cited by 71
Unleashing TNF cytotoxicity to enhance cancer immunotherapy
Freeman, A. J., Kearney, C. J., Silke, J., & Oliaro, J. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.10.003 · Cited by 69
BAF155 methylation drives metastasis by hijacking super-enhancers and subverting anti-tumor immunity
Kim, E., Liu, P., Zhang, S., Donahue, K., Wang, Y., Schehr, J. L., Wolfe, S. K., Dickerson, A., Lü, L., Rui, L., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1122 · Cited by 69
Dufva, O., Gandolfi, S., Huuhtanen, J., Dashevsky, O., Duàn, H., Saeed, K., Klievink, J., Nygren, P. J., Bouhlal, J., Lahtela, J., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.11.008 · Cited by 77
Muto, S., Enta, A., Maruya, Y., Inomata, S., Yamaguchi, H., Mine, H., Takagi, H., Ozaki, Y., Watanabe, M., Inoue, T., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11010190 · Cited by 68
PBRM1, SETD2 and BAP1 — the trinity of 3p in clear cell renal cell carcinoma
Walton, J., Lawson, K. A., Prinos, P., Finelli, A., Arrowsmith, C. H., & Ailles, L. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00659-1 · Cited by 74
Deregulation of SPOP in Cancer
Zhang, H., Jin, X., & Huang, H. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2801 · Cited by 66
Yan, X., Chen, D., Wang, Y., Guo, Y., Tong, C., Wei, J., Zhang, Y., Wu, Z., & Han, W. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00915-1 · Cited by 65
Roehle, K., Li, Q., Ventre, K. S., Heid, D., Ali, L. R., Lenehan, P. J., Heckler, M., Crowley, S. J., Stump, C. T., Ro, G., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf5058 · Cited by 63
Self-citationA T cell resilience model associated with response to immunotherapy in multiple tumor types
Zhang, Y., Vu, T., Palmer, D. C., Kishton, R. J., Gong, L., Huang, J., Nguyen, T., Chen, Z., Smith, C., Livák, F., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01799-y · Cited by 64
Self-citationEpigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease
Κhan, P., Siddiqui, J. A., Maurya, S. K., Lakshmanan, I., Jain, M., Ganti, A. K., Salgia, R., Batra, S. K., & Nasser, M. W. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.11.006 · Cited by 64
Vries, N. L. D., Mahfouz, A. E., Koning, F., & de Miranda, N. F. C. C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01254 · Cited by 58
Bashash, D., Zandi, Z., Kashani, B., Pourbagheri‐Sigaroodi, A., Salari, S., & Ghaffari, S. H. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30575 · Cited by 62
Targeting Chromatin-Remodeling Factors in Cancer Cells: Promising Molecules in Cancer Therapy
Zhang, F.-L., & Li, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112815 · Cited by 63
Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer
Sang, W., Zhou, Y., Chen, H., Yu, C., Dai, L., Liu, Z., Chen, L., Fang, Y., Ma, P., Wu, X., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0584 · Cited by 61
CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment
Xing, H., & Meng, L. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0322-9 · Cited by 61
Fakhri, S., Moradi, S. Z., Yarmohammadi, A., Narimani, F., Wallace, C. E., & Bishayee, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.834072 · Cited by 66
Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling
Apriamashvili, G., Vredevoogd, D. W., Krijgsman, O., Bleijerveld, O. B., Ligtenberg, M. A., de Bruijn, B., Boshuizen, J., Traets, J. J. H., Altimari, D. M. D., Vliet, A. V., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29442-x · Cited by 59
Engineering immune-evasive allogeneic cellular immunotherapies
Martin, K. E., Hammer, Q., Perica, K., Sadelain, M., & Malmberg, K. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01022-8 · Cited by 64
SMARCA4 mutations in KRAS ‐mutant lung adenocarcinoma: a multi‐cohort analysis
Liu, L., Ahmed, T., Petty, W. J., Grant, S. C., Ruiz, J., Lycan, T. W., Topaloĝlu, Ü., Chou, P., Miller, L. D., Hawkins, G. A., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12831 · Cited by 58
Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors
Shi, S., Gu, S. S., Han, T., Zhang, W., Huang, L., Li, Z., Pan, D., Fu, J., Ge, J., Brown, M. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0778 · Cited by 57
Self-citationPrognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
Yan, X., Zhang, S., Deng, Y., Wang, P., Hou, Q., & Xu, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01050 · Cited by 59
CRISPR-Based Tools in Immunity
Simeonov, D. R., & Marson, A. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041522 · Cited by 57
Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers
Forrest, S. J., Al‐Ibraheemi, A., Doan, D., Ward, A., Clinton, C. M., Putra, J., Pinches, R. S., Kadoch, C., Chi, S. N., DuBois, S. G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3089 · Cited by 57
Exploring liver cancer biology through functional genetic screens
Wang, C., Cao, Y., Yang, C. G., Bernards, R., & Qin, W. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00465-x · Cited by 58
Multifunctional Biomedical Materials Derived from Biological Membranes
Wang, Y., Xu, X., Chen, X., & Li, J. (2021) · Advanced Materials · doi:10.1002/adma.202107406 · Cited by 56
Loss of Rnf31 and Vps4b sensitizes pancreatic cancer to T cell-mediated killing
Frey, N., Tortola, L., Egli, D., Janjuha, S., Rothgangl, T., Marquart, K. F., Ampenberger, F., Köpf, M., & Schwank, G. (2022) · Nature Communications · doi:10.1038/s41467-022-29412-3 · Cited by 57
Ou, X., Ma, Q., Yin, W., Ma, X., & He, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.674467 · Cited by 58
Li, J., Mulvihill, T. S., Li, L., Barrott, J. J., Nelson, M. L., Wagner, L., Lock, I. C., Pozner, A., Lambert, S. L., Ozenberger, B. B., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1219 · Cited by 55
Wedge, M.-È., Jennings, V. A., Crupi, M. J. F., Poutou, J., Jamieson, T. R., Pelin, A., Pugliese, G., de Souza, C. T., Petryk, J., Laight, B. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29526-8 · Cited by 55
Poly(ADP‐ribosyl)ation of BRD7 by PARP1 confers resistance to DNA‐damaging chemotherapeutic agents
Hu, K., Wu, W., Li, Y., Lin, L., Chen, D., Yan, H., Xiao, X., Chen, H., Chen, Z., Zhang, Y., et al. (2019) · EMBO Reports · doi:10.15252/embr.201846166 · Cited by 55
Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence
Zhou, X., Qu, M., Tebon, P. J., Jiang, X., Wang, C., Xue, Y., Zhu, J., Zhang, S., Öklü, R., Sengupta, S., et al. (2020) · Advanced Science · doi:10.1002/advs.202001447 · Cited by 55
Lei, A., Chen, L., Zhang, M., Yang, X., Xu, L., Cao, N., Zhang, Z., & Cao, Y. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00422 · Cited by 54
Orlando, K. A., Nguyen, V. Q., Raab, J. R., Walhart, T. A., & Weissman, B. E. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1605905 · Cited by 55
Yuan, B., Clark, C. A., Wu, B., Yang, J., Drerup, J. M., Li, T., Jin, V. X., Hu, Y., Curiel, T. J., & Li, R. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001932 · Cited by 57
Xiong, Y., Wang, Z., Zhou, Q., Zeng, H., Zhang, H., Liu, Z., Huang, Q., Wang, J., Chang, Y., Xia, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000447 · Cited by 53
Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
Puccini, A., Battaglin, F., Iaia, M. L., Lenz, H., & Salem, M. E. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000404 · Cited by 53
Zheng, N., Wang, T., Luo, Q., Liu, Y., Yang, J., Zhou, Y., Xie, G., Ma, Y., Yuan, X., & Shen, L. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2210959 · Cited by 53
Biomarkers for Response to Immune Checkpoint Blockade
Ganesan, S., & Mehnert, J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033604 · Cited by 51
Correa, S., Meany, E. L., Gale, E. C., Klich, J. H., Saouaf, O. M., Mayer, A. T., Xiao, Z., Liong, C. S., Brown, R. A., Maikawa, C. L., et al. (2022) · Advanced Science · doi:10.1002/advs.202103677 · Cited by 48
Cancer immunology data engine reveals secreted AOAH as a potential immunotherapy
Gong, L., Luo, J., Yang, E., Ru, B., Qi, Z., Yang, Y., Rani, A., Purohit, A., Zhang, Y., Guan, G., et al. (2025) · Cell · doi:10.1016/j.cell.2025.07.004 · Cited by 56
Self-citationClear cell carcinomas of the ovary and kidney: clarity through genomics
Ji, J. X. Y., Wang, Y. K., Cochrane, D. R., & Huntsman, D. D. (2018) · The Journal of Pathology · doi:10.1002/path.5037 · Cited by 52
Ning, H., HUANG, S. H., Yang, L., Zhi, R., Yan, H., Jin, J., Hu, Z., Guo, K., Liu, J., Yang, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34253-1 · Cited by 53
Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma
Zhou, Z., Chen, M.-J. M., Luo, Y., Mojumdar, K., Peng, X., Chen, H., Kumar, S. V., Akbani, R., Lu, Y., & Liang, H. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.012 · Cited by 49
Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma
Attalla, K., Weng, S., Voss, M. H., & Hakimi, A. A. (2020) · Urologic Clinics of North America · doi:10.1016/j.ucl.2020.04.002 · Cited by 51
How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy
Li, J., & Stanger, B. Z. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1420 · Cited by 54
Intratumoral hypoxia and mechanisms of immune evasion mediated by hypoxia-inducible factors
Semenza, G. L. (2021) · Physiology · doi:10.1152/physiol.00034.2020 · Cited by 64
Tsai, K. K., Huang, S., Northey, J. J., Liao, W., Hsu, C., Cheng, L., Werner, M. E., Chuu, C., Chatterjee, C., Lakins, J. N., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00375-0 · Cited by 53
Dmello, C., Zhao, J., Chen, L., Gould, A., Castro, B. A., Arrieta, V. A., Zhang, D. Y., Kim, K.-S., Kanojia, D., Zhang, P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36878-2 · Cited by 49
Givechian, K. B., Wnuk, K., Garner, C. P., Benz, S. C., Garbán, H., Rabizadeh, S., Niazi, K., & Soon‐Shiong, P. (2018) · npj Genomic Medicine · doi:10.1038/s41525-018-0054-7 · Cited by 48
Lin, E., Liu, X., Liu, Y., Zhang, Z., Xie, L., Tian, K., Liu, J., & Yu, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.653358 · Cited by 51
Self-citationThe role of mitochondria in the resistance of melanoma to PD-1 inhibitors
Du, F., Yang, L.-H., Liu, J., Wang, J., Fan, L., Duangmano, S., Liu, H., Liu, M., Wang, J., Zhong, X., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04200-9 · Cited by 47
Zhang, W., Zhu, Y., Liu, H., Zhang, Y., Liu, H., Adegboro, A. A., Dang, R., Dai, L., Wanggou, S., & Li, X. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00570-5 · Cited by 49
Boumelha, J., de Castro, A., Bah, N. K., Cha, H., Trécesson, S. D. C., Rana, S., Tomaschko, M., Anastasiou, P., Mugarza, E., Moore, C., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2627 · Cited by 51
PBRM1 bromodomains variably influence nucleosome interactions and cellular function
Slaughter, M. J., Shanle, E. K., McFadden, A. W., Hollis, E. S., Suttle, L. E., Strahl, B. D., & Davis, I. J. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003381 · Cited by 48
BIRC2 Expression Impairs Anti-Cancer Immunity and Immunotherapy Efficacy
Samanta, D., Huang, T. Y.-T., Shah, R., Yang, Y., Pan, F., & Semenza, G. L. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108073 · Cited by 49
Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy
Qin, Y., Huo, M., Liu, X., & Li, S. C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1368749 · Cited by 51
Self-citationSWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications
Fukumoto, T., Magno, E., & Zhang, R. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0368 · Cited by 47
Possible Biomarkers for Cancer Immunotherapy
Otoshi, T., Nagano, T., TACHIHARA, M. Y., & Nishimura, Y. (2019) · Cancers · doi:10.3390/cancers11070935 · Cited by 47
Targeting TANK-binding kinase 1 (TBK1) in cancer
Revach, O., Liu, S., & Jenkins, R. W. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1826929 · Cited by 49
Bai, X., Ni, J., Beretov, J., Graham, P., & Li, Y. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2021.06.001 · Cited by 50
Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma
Benboubker, V., Boivin, F., Dalle, S., & Caramel, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.873116 · Cited by 51
Treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go
Longo, V., Catino, A., Montrone, M., Montagna, E. S., Pesola, F., Marech, I., Pizzutilo, P., Nardone, A., Perrone, A., Gesualdo, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063237 · Cited by 47
Integrated molecular drivers coordinate biological and clinical states in melanoma
Conway, J. R., Dietlein, F., Taylor-Weiner, A. N., AlDubayan, S. H., Vokes, N. I., Keenan, T. E., Reardon, B. M., He, M. X., Margolis, C. A., Weirather, J. L., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-00739-1 · Cited by 44
Molecular Determinants of Soft Tissue Sarcoma Immunity: Targets for Immune Intervention
Tazzari, M., Bergamaschi, L., Vita, A. D., Collini, P., Barisella, M., Bertolotti, A., Ibrahim, T., Pasquali, S., Castelli, C., & Vallacchi, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147518 · Cited by 45
Mechanism of Action of the SWI/SNF Family Complexes
Chen, K., Yuan, J., Sia, Y., & Chen, Z. (2023) · Nucleus · doi:10.1080/19491034.2023.2165604 · Cited by 45
Dervovic, D., Malik, A., Chen, E. L. Y., Narimatsu, M., Adler, N., Afiuni‐Zadeh, S., Krenbek, D., Martinez, S., Tsai, R., Boucher, J. G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38841-7 · Cited by 48
Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities
Serresi, M., Siteur, B., Hulsman, D., Schmitt, M. J., Lieftink, C., Morris, B., Cesaroni, M., Proost, N., Beijersbergen, R. L., van Lohuizen, M., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20180801 · Cited by 45
SLFN11 can sensitize tumor cells towards IFN-γ-mediated T cell killing
Mezzadra, R., de Bruijn, M. J. W., Jae, L. T., Gomez, R., Duursma, A. M., Scheeren, F. A., Brummelkamp, T. R., & Schumacher, T. N. (2019) · PLoS ONE · doi:10.1371/journal.pone.0212053 · Cited by 45
Zhou, M., Yuan, J., Deng, Y., Fan, X., & Shen, J. (2021) · Oncogenesis · doi:10.1038/s41389-020-00296-6 · Cited by 49
Hou, J., Wang, Y., Shi, L., Chen, Y., Xu, C., Saeedi, A., Pan, K., Bohat, R., Egan, N. A., McKenzie, J. A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001819 · Cited by 46
Li, Y., Yang, X., Zhu, W., Xu, Y., Ma, J., He, C., & Wang, F. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02757-x · Cited by 44
Immunogenomic cancer evolution: A framework to understand cancer immunosuppression
Kumagai, S., Momoi, Y., & Nishikawa, H. (2025) · Science Immunology · doi:10.1126/sciimmunol.abo5570 · Cited by 46
Platelet-derived TLT-1 promotes tumor progression by suppressing CD8+ T cells
Tyagi, T., Jain, K., Yarovinsky, T. O., Chiorazzi, M., Du, J., Castro, C., Griffin, J. L., Korde, A., Martin, K. A., Takyar, S. S., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20212218 · Cited by 45
Gong, Z., Jia, Q., Chen, J., Diao, X., Gao, J., Wang, X., & Zhu, B. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.01.024 · Cited by 43
Tao, S., Liang, S., Zeng, T., & Yin, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1043667 · Cited by 46
Huang, L., Zhu, H., & Shi, Y. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01734-x · Cited by 48
Chabanon, R. M., Morel, D., & Postel-Vinay, S. C. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.018 · Cited by 44
PROTACs: New method to degrade transcription regulating proteins
Hu, B.-C., Zhou, Y., Sun, D., Yang, Y., Liu, Y., Li, X., Li, H., & Chen, L. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112698 · Cited by 43
Epigenetic Regulation in Melanoma: Facts and Hopes
Giunta, E. F., Arrichiello, G., Curvietto, M., Pappalardo, A., Bosso, D., Rosanova, M., Diana, A., Giordano, P., Petrillo, A., Federico, P., et al. (2021) · Cells · doi:10.3390/cells10082048 · Cited by 47
Rassy, E., Boussios, S., & Pavlidis, N. A. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13583 · Cited by 42
Chen, D., Liu, P., Lu, X., Li, J., Qi, D., Zang, L., Lin, J., Liu, Y., Zhai, S., Fu, D., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03042-7 · Cited by 43
Burgers, F. H., van der Mijn, J. C., Seijkens, T. T. P., Jedema, I., Bex, A., & Haanen, J. B. A. G. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-00983-w · Cited by 49
Niu, W., Luo, Y., Zhou, Y., Li, M., Wu, C., Duan, Y., Wang, H., Fan, S., Li, Z., Xiong, W., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1493-4 · Cited by 44
Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors
Olbryt, M., Rajczykowski, M., & Widłak, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114071 · Cited by 42
Saigí, M., Alburquerque-Béjar, J. J., & Sánchez‐Céspedes, M. (2019) · Oncogene · doi:10.1038/s41388-019-0855-x · Cited by 40
Wang, Z., Li, K., Chen, W., Wang, X., Huang, Y., Wang, W., Wu, W., Cai, Z., & Huang, W. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03362-4 · Cited by 40
Hu, B., Lin, J., Yang, X., & Sang, X. (2020) · Cell Proliferation · doi:10.1111/cpr.12791 · Cited by 40
CRISPR screen in mechanism and target discovery for cancer immunotherapy
Liu, D., Zhao, X., Tang, A., Xu, X., Liu, S., Zha, L., Ma, W., Zheng, J., & Shi, M. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188378 · Cited by 44
Altered BAF occupancy and transcription factor dynamics in PBAF-deficient melanoma
Carcamo, S., Nguyen, C. B., Grossi, E., Filipescu, D., Alpsoy, A., Dhiman, A., Sun, D., Narang, S., Imig, J., Martin, T. C., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110637 · Cited by 42
Gu, H., Yan, W., Wang, Y., Xu, W., Huang, L., Yang, J., Zhai, B., Wang, H., Su, Y., Zhu, Q., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01452 · Cited by 40
Luo, C., Zhang, R., Guo, R., Wu, L., Xue, T., He, Y., Jin, Y., Zhao, Y., Zhang, Z., Zhang, P., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.02.007 · Cited by 37
Self-citationChromatin remodeling and cancer: the critical influence of the SWI/SNF complex
Hao, F., Zhang, Y., Hou, J., & Zhao, B. (2025) · Epigenetics & Chromatin · doi:10.1186/s13072-025-00590-w · Cited by 47
Nishio, S., Matsumoto, K., Takehara, K., Kawamura, N., Hasegawa, K., Takeshima, N., Aoki, D., Kamiura, S., Arakawa, A., Kondo, E., et al. (2020) · Cancer Science · doi:10.1111/cas.14340 · Cited by 40
Methodological Development of Combination Drug and Radiotherapy in Basic and Clinical Research
Chargari, C., Lévy, A., Paolettí, X., Soria, J., Massard, C., Weichselbaum, R. R., & Deutsch, É. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4155 · Cited by 40
Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications
Vanni, I., Tanda, E. T., Dalmasso, B., Pastorino, L., Andreotti, V., Bruno, W., Boutros, A., Spagnolo, F., & Ghiorzo, P. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00172 · Cited by 43
ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma
Fukumoto, T., Lin, J., Fatkhutdinov, N., Liu, P., Somasundaram, R., Herlyn, M., Zhang, R., & Nishigori, C. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.11.026 · Cited by 40
Metadata
- Authors
- Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., Long, H. W., Yuan, G.-C., Doench, J., Brown, M., Liu, X. S., & Wucherpfennig, K. W.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Astellas Pharma (Japan) (JP)
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- Broad Institute (US)
- Harvard University (US)
- Corresponding author
- Pan, Deng
- Kobayashi, Aya
- Jiang, Peng
- Liu, X. Shirley
- Wucherpfennig, Kai W.
- ORCID
- Venue
- Science
- Published
- 2018-02-16
- Volume
- 359
- Issue
- 6377
- Pages
- 770-775
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC5953516
- OpenAlex
- W2782124401
- Cited by
- 852
- References
- 51
- Citations by year
- 2026: 39 · 2025: 96 · 2024: 92 · 2023: 107 · 2022: 123 · 2021: 117 · 2020: 143 · 2019: 86 · 2018: 47
- FWCI
- 36.93
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (R01CA173750)
- Astellas Pharma
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- SWI/SNF complex, PBRM1, immune checkpoint inhibitors, T cell-mediated killing, antitumor immunity, interferon-gamma, renal cell carcinoma, chromatin regulation
- MeSH terms
- CRISPR-Associated Protein 9, Bromodomain Containing Proteins, Animals, Bacterial Proteins, Chromosomal Proteins, Non-Histone, Cytotoxicity, Immunologic, DNA-Binding Proteins, Endonucleases, Genetic Testing, Humans, Immunotherapy, Interferon-gamma, Melanoma, Experimental, Skin Neoplasms, T-Lymphocytes, Cytotoxic, Transcription Factors, HMGB Proteins, Cell Line, Tumor, Mice, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
